Bifeprunox in the Treatment of Schizophrenia

Solvay

Status and phase: Completed; Phase 3

Conditions: Schizophrenia

Treatments: Drug: bifeprunox

Study type: Interventional

Funder types: Industry

Identifiers

NCT00193713

S154.3.004

Details and patient eligibility

About

Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of schizophrenia
• understand nature of study
• able to be managed in out-patient setting for long-term bifeprunox treatment

Exclusion criteria

• current primary diagnosis other than schizophrenia
• suicide risk
• diagnosis or history of substance abuse
• uncontrolled hypertension

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind